Brazil Healthcare Regulator Says Patient in AstraZeneca Coronavirus Vaccine Trial Dies
Anvisa, Brazil's healthcare regulator, said Wednesday that it was told a patient in a late-stage clinical trial of AstraZeneca's (NYSE: AZN) COVID-19 vaccine candidate has died. Citing medical confidentiality, it did not provide any details about the patient, the possible cause of death, and whether the patient was being administered the vaccine or a placebo. It only divulged that the patient was Brazilian.
Anvisa did say that the trial, aimed at gauging the efficacy of AZD1222, developed in coordination with the University of Oxford, would continue.
AstraZeneca has not yet responded to the regulator's announcement. A spokesperson from the university, quoted by CNBC, said that "there have been no concerns about safety of the clinical trial."
Source Fool.com
